Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07500467Completed

Upadacitinib for Refractory Takayasu Arteritis

Role: lead

NCT07080346Phase 2Completed

Upadacitinib for Refractory Behcet's Syndrome

Role: lead

NCT06662721Phase 2Completed

Baricitinib for Refractory Takayasu Arteritis

Role: lead

NCT05339217Phase 3Recruiting

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Role: lead

All 4 trials loaded